Is GlaxoSmithKline plc Just A Tracker Fund In Disguise?

GlaxoSmithKline plc (LON: GSK) remains a core holding for investors who are happy to take the slow road to riches.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Analysts say a lot of pleasant things about GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US). They remark upon its size and its solidity. They name it as a core portfolio holding, a building block for your long-term wealth. The ultimate ‘buy and forget’ stock. What does that sound like to you? To me, it sounds like the sales pitch for a FTSE 100 tracker fund.

Now that’s not necessarily a bad thing. I hold Glaxo, and I hold a tracker fund, the HSBC FTSE 100 Index. Both have served me well. But why hold both? After all, 4.4% of my tracker fund is actually made up of Glaxo, with its massive £80 billion market cap. The tracker gives me a dab of exposure to Glaxo’s steady, solid upside, while protecting me against its occasional excesses, such as the small matter of a Chinese bribery scandal. Do I really need to own the stock itself?

gskRisk, Reward And R&D

As with any individual company holding, there are greater risks than buying the whole index. Glaxo’s drugs pipeline may dry up. It may suffer a string of late-stage failures. The share price may tumble off a patent cliff. Reputational damage from China could prove more severe than expected. On the other hand, there are potentially higher rewards, if Glaxo outperforms, say, because its recent strong run of R&D approvals continues, management continues to drive down costs, or emerging market sales continue to outperform. So no, it’s more than a tracker. 

Does Glaxo offer greater defensive capabilities than the index, a reason often touted for holding this stock? To a degree, yes. As the table below shows, during the market meltdown of 2008, Glaxo fell around 22%, but my tracker fell nearly 29%. More impressively, in 2011 the FTSE 100 dropped around 3.5%, but Glaxo rose nearly 22%. It then underperformed a rising market in 2012, only to seriously outperform in 2013.

Total return GlaxoSmithKline HSBC FTSE 100
2013 28.36% 18.04%
2012 0.70% 10.36%
2011 21.97% -3.68%
2010 -2.44% 13.04%
2009 18.34% 26.05%
2008 -21.79% -28.76

Similarly, cumulative performance figures show that over three years, Glaxo has returned 44% against my tracker’s 27%. Over five years, it severely underperformed, returning 64% against 101% for the index. Win or lose, that is quite a wide tracking error.

Cumulative return GlaxoSmithKline HSBC FTSE 100
Six months 4.5% 1.5%
One year 9% 6%
Three years 44% 27%
Five years 64% 101%

The only reason to invest in direct equities is that you think you’re clever enough to beat the market, by picking more winners than losers. So if you the Glaxo will outperform the market, then it makes sense to buy it. But if you’re idly buying it as a core holding and building block, it would make more sense to buy a tracker.

Index Thrasher

There are other reasons to invest in Glaxo rather than the entire index. You might think it is undervalued, for example. Although if anything, Glaxo is a little costly right now, at 14.8 times earnings against 13.25 times for the index. Or maybe you’re looking for higher income. My tracker currently yields 3.43%. Glaxo yields 4.7%. So rather than index tracker, at times it can be an index thrasher.

To answer my question: no, Glaxo isn’t a FTSE 100 tracker in disguise. It has added elements of risk and reward. So don’t buy it purely for its defensive solidity. It has a lot more to offer than that.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones owns Glaxo and the HSBC FTSE 100 Index tracker. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Young black man looking at phone while on the London Overground
Investing Articles

1 delicious penny stock I reckon can deliver juicy returns and growth

This food delivery penny stock has experienced a surge in performance and uptake recently. Our writer is excited by its…

Read more »

Investing Articles

If I’d bought Rolls-Royce shares the day Tufan Erginbilgiç joined here’s what I’d have now

Harvey Jones is startled by just how fast the Rolls-Royce share price has risen since its transformative CEO took over.…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

How much do I need to invest in Lloyds shares to earn income of £1,000 a year?

Harvey Jones is getting income and growth from his Lloyds shares but wished he'd bought more of them. So he's…

Read more »

Illustration of flames over a black background
Investing Articles

Down 75%! Will the Saga share price ever be loved again?

The last few years have been incredibly difficult for those watching the Saga share price. But what does the future…

Read more »

Investing Articles

What kind of return could I expect by investing £100 monthly in a Stocks and Shares ISA?

Using a Stocks and Shares ISA to avoid capital gains tax could grow a £100 monthly investment into a second…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Can strong operational momentum keep the Informa share price rising?

FTSE 100 company Informa has been performing well, but this may be just the beginning of a multi-year trend for…

Read more »

Market Movers

What’s going on with the Britvic share price?

Jon Smith flags up why Britvic's share price is surging on Friday, but believes that the company is in a…

Read more »

Cheerful young businesspeople with laptop working in office
Dividend Shares

2 super-cheap passive income shares I’m eyeing up right now

Jon Smith discusses two of his favourite passive income shares in the banking and property sectors, both featuring yields above…

Read more »